{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:55:02Z","timestamp":1791460502818,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"DOI":"10.1007\/s10637-026-01635-x","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:17:45Z","timestamp":1791458265000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy of CLDN18.2-directed regimens in advanced gastric\/gastroesophageal junction adenocarcinoma: a meta-analysis of single-arm trials"],"prefix":"10.1007","author":[{"given":"Yue","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkai","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinhang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"1635_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"1635_CR2","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.Ccr-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G et al (2008) Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 14:7624\u20137634. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-08-1547","journal-title":"Clin Cancer Res"},{"key":"1635_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.gene.2011.04.007","volume":"481","author":"O T\u00fcreci","year":"2011","unstructured":"T\u00fcreci O, Koslowski M, Helftenbein G, Castle J, Rohde C, Dhaene K et al (2011) Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene 481:83\u201392. https:\/\/doi.org\/10.1016\/j.gene.2011.04.007","journal-title":"Gene"},{"key":"1635_CR4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/ijc.28400","volume":"134","author":"S W\u00f6ll","year":"2014","unstructured":"W\u00f6ll S, Schlitter AM, Dhaene K, Roller M, Esposito I, Sahin U et al (2014) Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer 134:731\u2013739. https:\/\/doi.org\/10.1002\/ijc.28400","journal-title":"Int J Cancer"},{"key":"1635_CR5","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1369\/0022155411420569","volume":"59","author":"M Tanaka","year":"2011","unstructured":"Tanaka M, Shibahara J, Fukushima N, Shinozaki A, Umeda M, Ishikawa S et al (2011) Claudin-18 is an early-stage marker of pancreatic carcinogenesis. J Histochem Cytochem 59:942\u2013952. https:\/\/doi.org\/10.1369\/0022155411420569","journal-title":"J Histochem Cytochem"},{"key":"1635_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae238","author":"Y Kwak","year":"2025","unstructured":"Kwak Y, Kim TY, Nam SK, Hwang HJ, Han D, Oh HJ et al (2025) Clinicopathologic and molecular characterization of stages II-IV gastric cancer with claudin 18.2 expression. Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyae238","journal-title":"Oncologist"},{"key":"1635_CR7","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1200\/JCO.2025.43.16_suppl.4037","volume":"43","author":"SY Rha","year":"2025","unstructured":"Rha SY, Kwon WS, Lee C-k, Jung M, Shin S-J, Kim H et al (2025) Co-expressing pattern of multiple biomakers and dynamic change of Claudin18.2 expression after systemic chemotherapy in advanced gastric cancer. J Clin Oncol 43:4037\u20134037. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4037","journal-title":"J Clin Oncol"},{"key":"1635_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4132\/jptm.2025.09.11","volume":"60","author":"H Wu","year":"2026","unstructured":"Wu H, Li M, Wang G, Liao P, Zhang P, Yang L et al (2026) Clinicopathological and molecular mechanisms of CLDN18.2 in gastric cancer aggressiveness: a high-risk population study with multi-omics profiling. J Pathol Transl Med 60:47\u201357. https:\/\/doi.org\/10.4132\/jptm.2025.09.11","journal-title":"J Pathol Transl Med"},{"key":"1635_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"1635_CR10","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J (2003) Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg 73:712\u2013716. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x","journal-title":"ANZ J Surg"},{"key":"1635_CR11","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1038\/s41591-025-03783-8","volume":"31","author":"J Liu","year":"2025","unstructured":"Liu J, Yang JW, Sun YP, Gong JF, Yue JB, Pan YY et al (2025) CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial. Nat Med 31:3028\u20133036. https:\/\/doi.org\/10.1038\/s41591-025-03783-8","journal-title":"Nat Med"},{"key":"1635_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115808","volume":"230","author":"C Bai","year":"2025","unstructured":"Bai C, Zheng Y, Sun M, Ying J, Zhou F, Yu Y et al (2025) Tecotabart vedotin in Claudin 18.2-positive advanced gastric\/gastroesophageal junction cancer: a Bayesian phase 1\/2 clinical trial. Eur J Cancer 230:115808. https:\/\/doi.org\/10.1016\/j.ejca.2025.115808","journal-title":"Eur J Cancer"},{"key":"1635_CR13","doi-asserted-by":"publisher","first-page":"S892","DOI":"10.1016\/j.annonc.2024.08.1499","volume":"35","author":"J Gong","year":"2024","unstructured":"Gong J, Liu F, Jin Z, Zhang M, Zhang S, Zhang Y et al (2024) A phase I\/II study of FG-M108 plus capecitabine and oxaliplatin (CAPOX) as first-line (1L) treatment for patients with CLDN18.2+\/HER2-advanced gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma. Ann Oncol 35:S892\u2013S892. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.1499","journal-title":"Ann Oncol"},{"key":"1635_CR14","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1158\/1078-0432.Ccr-23-0204","volume":"29","author":"SJ Klempner","year":"2023","unstructured":"Klempner SJ, Lee KW, Shitara K, Metges JP, Lonardi S, Ilson DH et al (2023) ILUSTRO: phase II multicohort trial of zolbetuximab in patients with advanced or metastatic Claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res 29:3882\u20133891. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-0204","journal-title":"Clin Cancer Res"},{"key":"1635_CR15","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1158\/1078-0432.Ccr-24-4280","volume":"31","author":"G Ku","year":"2025","unstructured":"Ku G, Shen L, Dayyani F, Kratz J, Liang XJ, Liu FN et al (2025) A first-in-human study of givastomig, a CLDN18.2 and 4\u20131BB bispecific antibody, as monotherapy in patients with CLDN18.2-positive advanced or metastatic solid tumors. Clin Cancer Res 31:4944\u20134952. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-4280","journal-title":"Clin Cancer Res"},{"key":"1635_CR16","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi C, Liu C, Gong J, Liu D, Wang X, Zhang P et al (2024) Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat Med 30:2224\u20132234. https:\/\/doi.org\/10.1038\/s41591-024-03037-z","journal-title":"Nat Med"},{"key":"1635_CR17","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1111\/cas.15684","volume":"114","author":"K Shitara","year":"2023","unstructured":"Shitara K, Kawazoe A, Hirakawa A, Nakanishi Y, Furuki S, Fukuda M et al (2023) Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma. Cancer Sci 114:1606\u20131615. https:\/\/doi.org\/10.1111\/cas.15684","journal-title":"Cancer Sci"},{"key":"1635_CR18","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/annonc\/mdz199","volume":"30","author":"O T\u00fcreci","year":"2019","unstructured":"T\u00fcreci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D et al (2019) A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol 30:1487\u20131495. https:\/\/doi.org\/10.1093\/annonc\/mdz199","journal-title":"Ann Oncol"},{"key":"1635_CR19","doi-asserted-by":"publisher","first-page":"S487","DOI":"10.1016\/j.annonc.2024.08.676","volume":"35","author":"RH Xu","year":"2024","unstructured":"Xu RH, Ruan D, Luo S, Liang X, Niu Z, Dang Q et al (2024) CLDN18.2 targeted antibody-drug conjugate (ADC), SHR-A1904, in patients (pts) with gastric\/gastroesophageal junction cancer (GC\/GEJC): a phase I study. Ann Oncol 35:S487\u2013S488. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.676","journal-title":"Ann Oncol"},{"key":"1635_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04306-9","author":"K Shitara","year":"2026","unstructured":"Shitara K, Shoji H, Fazio N, Lonardi S, Lee K-W, Bai L-Y et al (2026) First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. Nat Med. https:\/\/doi.org\/10.1038\/s41591-026-04306-9","journal-title":"Nat Med"},{"key":"1635_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/s1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176\u2013181. https:\/\/doi.org\/10.1016\/s1053-4296(03)00031-6","journal-title":"Semin Radiat Oncol"},{"key":"1635_CR22","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/onc.2009.356","volume":"29","author":"A Tesniere","year":"2010","unstructured":"Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F et al (2010) Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29:482\u2013491. https:\/\/doi.org\/10.1038\/onc.2009.356","journal-title":"Oncogene"},{"key":"1635_CR23","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/s0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA et al (2023) Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401:1655\u20131668. https:\/\/doi.org\/10.1016\/s0140-6736(23)00620-7","journal-title":"Lancet"},{"key":"1635_CR24","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D et al (2023) Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 29:2133\u20132141. https:\/\/doi.org\/10.1038\/s41591-023-02465-7","journal-title":"Nat Med"},{"key":"1635_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin U, T\u00fcreci \u00d6, Manikhas G, Lordick F, Rusyn A, Vynnychenko I et al (2021) FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol 32:609\u2013619. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.005","journal-title":"Ann Oncol"},{"key":"1635_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.149942","volume":"339","author":"M Zhang","year":"2026","unstructured":"Zhang M, Yuan H, Li X, Yin J, Qi F, Chen J et al (2026) Development and characterization of CR101-ADC, a fully-human anti-claudin18.2 monoclonal antibody-drug conjugate. Int J Biol Macromol 339:149942. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.149942","journal-title":"Int J Biol Macromol"},{"key":"1635_CR27","doi-asserted-by":"publisher","first-page":"S1524","DOI":"10.1016\/j.annonc.2023.10.270","volume":"34","author":"F Lordick","year":"2023","unstructured":"Lordick F, Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger PC et al (2023) Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma. Ann Oncol 34:S1524\u2013S1524. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.270","journal-title":"Ann Oncol"},{"key":"1635_CR28","doi-asserted-by":"publisher","first-page":"S1322","DOI":"10.1016\/j.annonc.2023.10.08","volume":"34","author":"JA Ajani","year":"2023","unstructured":"Ajani JA, Lordick F, Bang YJ, Enzinger PC, Ilson DH, Shah MA et al (2023) Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma. Ann Oncol 34:S1322\u2013S1322. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.08","journal-title":"Ann Oncol"},{"key":"1635_CR29","doi-asserted-by":"publisher","first-page":"S1121","DOI":"10.1016\/j.annonc.2025.08.2757","volume":"36","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Su D, Ma J, Zhang Y, Chen Y, Qu X et al (2025) 2138P First-in-human study of BA1301, a novel CLDN18.2-targeting antibody-drug conjugate in advanced solid tumors. Ann Oncol 36:S1121\u2013S1122. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.2757","journal-title":"Ann Oncol"},{"key":"1635_CR30","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1200\/JCO.2026.44.16_suppl.4031","volume":"44","author":"D Su","year":"2026","unstructured":"Su D, Wang X, Zhang Y, Qu J, Chen Y, Liu Z et al (2026) CLDN18.2\u2013targeting antibody-drug conjugate BA1301 in advanced solid tumors: results from a phase I clinical trial. J Clin Oncol 44:4031\u20134031. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.4031","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01635-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01635-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01635-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:17:46Z","timestamp":1791458266000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-026-01635-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":30,"alternative-id":["1635"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01635-x","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"12 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This is a meta-analysis of previously published studies.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}